Advanced Accelerator Applications SA
Division of Novartis AG
www.adacap.com
Latest From Advanced Accelerator Applications SA
CDER's Novel Approvals In 2018 Show Remarkable Review Consistency
Novartis R&D Chief Tsai On 2019 Goals, Priorities, BD And Digital Advances
R&D head John Tsai spoke with Scrip about culture change at Novartis as it moves toward advanced therapy platforms and embraces digital technologies, and offered a peek into what’s in store for R&D in 2019 and beyond.
In A Record Year For US FDA Approvals, Pfizer Came Out On Top
Scrip’s Top Five Stories Of 2018
A look back at the Scrip stories that piqued the most interest for our readers in 2018.
Company Information
- Industry
- In Vitro Diagnostics
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Molecular Imaging
-
Diagnostic Imaging Equipment & Supplies
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
- Therapeutic Areas
- Cancer
- Cardiovascular
- Infectious & Viral Diseases
- Inflammation
- Neurology, Nervous System
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
France
-
France
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Novartis AG
- Senior Management
-
Stefano Buono, CEO
Heinz Mausli, CFO
Claude Hariton, Head, R&D
Gerard Ber, COO - Contact Info
-
Advanced Accelerator Applications SA
Phone: 4 50 99 30 70
20 Rue Diesel
Saint Genis Pouilly, 01630
France
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice